Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > AGN Patent Application News Summary
View:
Post by StockHawk1 on Apr 17, 2023 6:54pm

AGN Patent Application News Summary

Algernon Pharmaceuticals (AGN.c AGNPF) closed in the green today after announcing it  received a Notice of Allowance from the US Patent and Trademark Office for its patent application for its lead chronic kidney disease (CKD) drug Repirinast. 


Repirinast has shown promising results in reducing hepatic fibrosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH). 


Repirinast is also being investigated as a treatment for CKD, as patients with NAFLD have an increased risk of developing CKD. 


Repirinast works by binding to receptors on mast cells to prevent their degranulation, which AGN believes could help prevent fibrosis in multiple organs, including the kidneys and the liver.


More here: 

https://www.globenewswire.com/news-release/2023/04/17/2647769/0/en/Algernon-Pharmaceuticals-Announces-Notice-of-Allowance-for-Method-of-Use-U-S-Patent-Application.html

Be the first to comment on this post
Algernon Pharmaceuticals Inc.